Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 6/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787990 | 1.00 | BRD4 (0.35) | BRD4GRM5IRAK4PDE4ACRHR1 | |
| SCHEMBL5599539 | 0.83 | IRAK4 (0.37) | BRD4IRAK4CRHR1 | |
| SCHEMBL5788374 | 0.83 | IRAK4 (0.37) | BRD4IRAK4CRHR1 | |
| SCHEMBL6305307 | 0.78 | CRHR1 (0.46) | GRM5PDE4ACRHR1PDE4BPDE4C | |
| SCHEMBL5787424 | 0.71 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL5843656 | 0.71 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5787466 | 0.71 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL6634034 | 0.70 | SYK (0.38) | GRM5PDE4APDE10APDE2APDE4B | |
| SCHEMBL5789970 | 0.70 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL7353116 | 0.69 | CRHR1 (0.38) | GRM5PDE4ACRHR1PDE10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923582-B1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2006-09-20 | — | — | EP | disclosed |
| US-6900217-B2 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | PFIZER INC. | 2002-10-17 | — | — | US | disclosed |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CHEN YUHPYNG L (US) | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151713-A1 | Substituted 6,5-hetero-bicyclic derivatives | CYP2D6, CYP2B6, CYP3A5 | BRD4 281/4885GRM5 623/4885IRAK4 4406/4885 |
| US-20010007867-A1 | SUBSTITUTED 6,5-HETERO-BICYCLIC DERIVATIVES | CYP2D6, CYP2B6, CYP3A5 | BRD4 427/4885GRM5 524/4885IRAK4 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.